Latest news with #CACMid&Small
Business Wire
4 days ago
- Business
- Business Wire
PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting
LYON, France--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as 'the Company' or 'PHAXIAM,' a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, asked Euronext to suspend trading of its shares listed on the Euronext Paris market starting today, Wednesday, June 18, 2025, before the market opens. Trading in PHAXIAM shares (FR001400K4B1) will remain suspended until the completion of the delisting procedure for PHAXIAM shares, which will take place shortly, following a request made to Euronext. As previously announced, no reimbursement will be made to shareholders. About PHAXIAM Therapeutics PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit
Business Wire
12-06-2025
- Business
- Business Wire
PHAXIAM Therapeutics Announces Judicial Liquidation and Delisting
LYON, France--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), hereinafter referred to as 'the Company' or 'PHAXIAM,' a biopharmaceutical company specializing in the development of innovative treatments for resistant bacterial infections, today announces that the Lyon Commercial Court has ordered the judicial liquidation (liquidation judiciaire) of the Company on June 11, 2025. As part of the judicial receivership proceedings (redressement judiciaire), two offers were submitted but were unable to result in the acquisition of PHAXIAM's assets. The Lyon Commercial Court has appointed Maître Pierre Martin as liquidator. Following this decision, PHAXIAM Therapeutics will request the delisting of its shares from Euronext, as previously announced. PHAXIAM reiterates that no reimbursement to shareholders can be made. Despite the efforts undertaken by the Company and its management to extend its financing horizon and maintain its operations, extremely challenging market conditions—particularly for small-cap listed biotech companies—did not allow for the implementation of a viable refinancing solution, leading the Company to file for receivership in early March 2025. Since 2017, PHAXIAM has provided more than 140 patients with phage-based treatments produced under pharmaceutical-grade standards, within a compassionate use framework. The Company sincerely hopes that these patients will continue to receive appropriate medical care and support despite the cessation of its activities. PHAXIAM would like to express its deep gratitude to all its stakeholders – including employees, partners, healthcare professionals, and shareholders – for their dedication and support throughout its journey. About PHAXIAM Therapeutics PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
Yahoo
11-06-2025
- Business
- Yahoo
Voltalia SA: Total number of shares and voting rights in the share capital as of May 31, 2025
Total number of shares and voting rights in the share capital as of May 31, 2025 (Articles L. 233-8 (II) of the French Commercial Code and 223-16 of the General Regulations of the French Financial Markets Authority) Date Total number of shares in the capital Number of theoretical voting rights Number of exercisable voting rights 05/31/2025 131 318 716 220 409 933 220 004 140 Next on the agenda: Q2 2025 Turnover, July 23, 2025 (after market close) About Voltalia ( Voltalia is an international player in the renewable energy sector. The Group produces and sells electricity generated from wind, solar, hydraulic, biomass and storage facilities that it owns and operates. Voltalia has generating capacity in operation and under construction of more than 3.3 GW and a portfolio of projects under development representing total capacity of 17.4 GW. Voltalia is also a service provider and supports its investor clients in renewable energy projects during all phases, from design to operation and a pioneer in the corporate market, Voltalia provides a global offer to private companies, ranging from the supply of green electricity and energy efficiency services to the local production of their own electricity. The Group has more than 2,000 employees and is present in 20 countries on 3 continents and is able to act worldwide on behalf of its clients. Voltalia is listed on the Euronext regulated market in Paris (FR0011995588 - VLTSA) and is included in the Enternext Tech 40 and CAC Mid&Small indices. The company is also included, amongst others, in the MSCI ESG ratings and the Sustainalytics ratings. VoltaliaInvestor Relations: invest@ +33 (0)1 81 70 37 00 Seitosei ActifinPress Contact: Jennifer Jullia Email: T. +33 (0)1 56 88 11 19 Attachment Total number of shares and voting rights in the share capital as of May 31, 2025Sign in to access your portfolio
Yahoo
05-06-2025
- Business
- Yahoo
PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing
LYON, France, June 05, 2025--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces that the Lyon Commercial Court ("Tribunal des activités économiques de Lyon") decided, during a hearing held on June 4, 2025, to postpone the offer review hearing and has set a new hearing date for Wednesday, June 11, 2025. At the end of the bid examination hearing, whether a bid is accepted or not, the Lyon Commercial Court will in any case soon pronounce the conversion of the judicial reorganization into judicial liquidation. In this context, the Company will request the delisting of PHAXIAM shares from Euronext. Furthermore, PHAXIAM draws investors' attention to the fact that, given the Company's level of indebtedness, the disposal proceeds received in the event a bid is adopted would not allow for any reimbursement of shareholders. About PHAXIAM Therapeutics PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit View source version on Contacts PHAXIAM Thibaut du Fayet CEO+33 4 78 74 44 38investors@ NewCap Mathilde Bohin / Dušan Orešanský Investor RelationsArthur RouilléMedia Relations+33 1 44 71 94 94phaxiam@
Business Wire
05-06-2025
- Business
- Business Wire
PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing
LYON, France--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative treatments for severe and resistant bacterial infections, announces that the Lyon Commercial Court ('Tribunal des activités économiques de Lyon') decided, during a hearing held on June 4, 2025, to postpone the offer review hearing and has set a new hearing date for Wednesday, June 11, 2025. At the end of the bid examination hearing, whether a bid is accepted or not, the Lyon Commercial Court will in any case soon pronounce the conversion of the judicial reorganization into judicial liquidation. In this context, the Company will request the delisting of PHAXIAM shares from Euronext. Furthermore, PHAXIAM draws investors' attention to the fact that, given the Company's level of indebtedness, the disposal proceeds received in the event a bid is adopted would not allow for any reimbursement of shareholders. About PHAXIAM Therapeutics PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit
